On June 17, 2026, Patrick NJ Schnegelsberg notified Picard Medical, Inc. (the "Company") of his decision to step down as Chief Executive Officer and as a member of the Board of Directors of the Company (the "Board"), effective June 18, 2026 (the "Separation Date"), in connection with a planned leadership transition. Mr. Schnegelsberg's departure was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. The Board thanks Mr. Schnegelsberg for his service and his contributions during a formative period for the Company.

The Board appointed Richard Fang, Ph.D., 60, as the Company’s Interim Chief Executive Officer, effective as of the Separation Date. Dr. Fang, former Chief Executive Officer and current Chairman of the Board, will serve as Interim Chief Executive Officer until a permanent successor has been appointed by the Board, and will continue to serve in his current role as Chairman. Dr. Fang served as the Chief Executive Officer from September 2021 until July 2023. Dr. Fang has served as a member of the Board since September 2021.

Dr. Fang is a founder and managing partner of Hunniwell Lake Ventures LLC, a med-tech focused venture capital firm founded in 2019. In 2005, Dr. Fang founded Reach Surgical, a minimally invasive surgical instruments company in California. He directed the growth and international expansion of Reach Surgical over a 15-year period, building a globally recognized brand presence across six continents. During that period, Dr. Fang managed the end-to-end lifecycle of three product lines and dozens of SKUs. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. In addition, Dr. Fang has over 20 years of hands-on expertise as a medical device industry professional, with a proven track record of success across the United States, including Johnson & Johnson. He has an MBA from the University of Cincinnati and a Ph.D. in Physics from Purdue University in Indianapolis.

There are no arrangements or understandings between Dr. Fang and any other persons pursuant to which he was selected as Interim Chief Executive Officer. Dr. Fang will receive an annual salary of $400,000 while he serves as Interim Chief Executive Officer. The information required to be disclosed under Item 404(a) of Securities and Exchange Commission Regulation S-K with respect to Dr. Fang is incorporated herein by reference from the disclosure included under the caption "Certain Relationships and Related Transactions" in the Registrant's preliminary Proxy Statement relating to the Registrant's 2026 Annual Meeting of Shareholders, which was filed with the SEC on June 12, 2026.